- Home
- TRC vs CELC Comparison
TRC vs CELC Comparison
Compare TRC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- CELC
- Stock Information
- Founded
- TRC 1843
- CELC 2011
- Country
- TRC United States
- CELC United States
- Employees
- TRC N/A
- CELC N/A
- Industry
- TRC Real Estate
- CELC Medical Specialities
- Sector
- TRC Finance
- CELC Health Care
- Exchange
- TRC Nasdaq
- CELC Nasdaq
- Market Cap
- TRC 440.9M
- CELC 440.0M
- IPO Year
- TRC N/A
- CELC 2017
- Fundamental
- Price
- TRC $18.65
- CELC $13.63
- Analyst Decision
- TRC
- CELC Strong Buy
- Analyst Count
- TRC 0
- CELC 6
- Target Price
- TRC N/A
- CELC $30.67
- AVG Volume (30 Days)
- TRC 98.7K
- CELC 206.7K
- Earning Date
- TRC 08-05-2025
- CELC 08-13-2025
- Dividend Yield
- TRC N/A
- CELC N/A
- EPS Growth
- TRC 298.28
- CELC N/A
- EPS
- TRC 0.08
- CELC N/A
- Revenue
- TRC $42,689,000.00
- CELC N/A
- Revenue This Year
- TRC $0.64
- CELC N/A
- Revenue Next Year
- TRC N/A
- CELC N/A
- P/E Ratio
- TRC $230.25
- CELC N/A
- Revenue Growth
- TRC 7.04
- CELC N/A
- 52 Week Low
- TRC $14.71
- CELC $7.58
- 52 Week High
- TRC $19.82
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- TRC 72.42
- CELC 62.38
- Support Level
- TRC $17.47
- CELC $12.48
- Resistance Level
- TRC $18.02
- CELC $14.19
- Average True Range (ATR)
- TRC 0.38
- CELC 0.75
- MACD
- TRC 0.15
- CELC 0.07
- Stochastic Oscillator
- TRC 98.00
- CELC 80.73
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.